Latest News in the pharma Industry

Research & Development

Aptuit expands capabilities and capacity in formulation development and safety assessment

Aptuit expands capabilities and capacity in formulation development and safety assessment

13 Oct 2016

Company's continued expansion allows it to further improve the transition of drug candidates from the discovery medicinal chemistry space through to formal regulatory based drug product development.

Read more 
PhoreMost and Cambridge Uni collaborate to identify innovative drug targets for neurodegenerative disease

PhoreMost and Cambridge Uni collaborate to identify innovative drug targets for neurodegenerative disease

12 Oct 2016

The studies have the potential to reveal novel insights for previously unknown autophagy signalling components, which could suggest rapid and innovative starting points for new drug treatments.

Read more 
FDA accepts sNDA for Avycaz

FDA accepts sNDA for Avycaz

11 Oct 2016

Application seeks to expand Avycaz label to include Phase III clinical data for the treatment of complicated urinary tract infections.

Read more 
Merck announces recipients of third annual €1 million ‘Grant for Oncology Innovation’ award

Merck announces recipients of third annual €1 million ‘Grant for Oncology Innovation’ award

10 Oct 2016

Grant established by Merck recognizes pioneering research in personalized treatment of solid tumours.

Read more 
Rapid and durable response in bladder cancer observed with nivolumab

Rapid and durable response in bladder cancer observed with nivolumab

10 Oct 2016

Data were presented at the 2016 European Society for Medical Oncology Congress.

Read more 
Enterprise Therapeutics secures £4M funding to advance therapies for patients with respiratory disease

Enterprise Therapeutics secures £4M funding to advance therapies for patients with respiratory disease

10 Nov 2016

Funding will allow the company to advance its research projects and move closer towards its goal of evaluating the efficacy of muco-regulatory drugs in patients.

Read more 
Allergan enters into licensing agreement with AstraZeneca to obtain worldwide rights to MEDI2070 inflammatory disorder development program

Allergan enters into licensing agreement with AstraZeneca to obtain worldwide rights to MEDI2070 inflammatory disorder development program

3 Oct 2016

MEDI2070 is in development as a next-generation IL-23-only targeted therapy for Crohn's disease and ulcerative colitis.

Read more 
Late-breaking data show Novartis' Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

Late-breaking data show Novartis' Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

2 Oct 2016

Cosentyx significantly superior to Stelara in delivering long-lasting skin clearance in psoriasis over 52 weeks.

Read more 
Researchers find a gap in the brain’s firewall against Parkinson’s disease

Researchers find a gap in the brain’s firewall against Parkinson’s disease

2 Oct 2016

NIH-funded mouse study identifies a key player in the progression of the disorder.

Read more 
Eppendorf to showcase solutions to common lab challenges at Lab Innovations 2016

Eppendorf to showcase solutions to common lab challenges at Lab Innovations 2016

28 Sep 2016

The company will exhibit and demonstrate a range of instruments and consumables from the liquid handling portfolio, including: pipettes & tips, manual and electronic dispensers and automated pipetting systems.

Read more 
Theratechnologies to move forward with development of new single vial formulation for Egrifta

Theratechnologies to move forward with development of new single vial formulation for Egrifta

28 Sep 2016

The introduction of a single vial presentation was part of commitments required by the FDA when it approved Egrifta (Tesamorelin for Injection).

Read more 
Biogen completes rolling submission of NDA to FDA for nusinersen as a treatment for spinal muscular atrophy

Biogen completes rolling submission of NDA to FDA for nusinersen as a treatment for spinal muscular atrophy

27 Sep 2016

Submission of Marketing Authorization Application to the EMA planned in the coming weeks.

Read more